Drug Discovery World

FEBRUARY 3, 2023

One of these candidates is VSV-SUDV, developed and tested by scientists at NIH’s National Institute of Allergy and Infectious Diseases in Hamilton, Montana. The fact that four control animals got sick demonstrates that pre-existing immunity to EBOV and VSV-EBOV has limited effect on protection from SUDV.

Vaccination 52

Vaccination Vaccine Genetic Engineering Protein 52

Drug Discovery World

JANUARY 22, 2024

Masaru Kanekiyo , Chief of Molecular Immunoengineering Section (MIS) of the Vaccine Research Center (VRC) at the US National Institute of Allergy and Infectious Diseases (NIAID), will present ‘Structural vaccinology for influenza’. His presentation is: ‘Accelerating biotherapeutics development through technology platforms’.

Engineer 59

Engineer Immune Response Drugs Vaccination 59

XTalks

NOVEMBER 30, 2023

Preclinical data demonstrated that HB-500 was well-tolerated, eliciting robust, high-quality and enduring immune responses, including antigen-specific T cells and antibodies, in non-human primates. In November 2023, Hookipa Pharma Inc., Notably, it significantly reduced viral load and clinical illness compared to a placebo.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

Scienmag

MARCH 1, 2021

Credit: Earlham Institute Respiratory viruses such as SARS-CoV-2 (causing COVID-19) can often catalyse an overactive immune response that leads to a life-threatening cycle, known as a cytokine storm.

Immune Response 59

Immune Response Bioinformatics Allergies Genetics 59

XTalks

SEPTEMBER 21, 2023

The trial’s primary objective is to assess the safety of VIR-1388 and its capacity to stimulate a specific immune response against HIV in study participants. This groundbreaking endeavor has received support from the National Institute of Allergy and Infectious Diseases (NIAID).

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

Scienmag

MARCH 19, 2021

Delivering vaccines directly to the lungs can boost immune responses to respiratory infections or lung cancer, study finds. CAMBRIDGE, MA — Many viruses infect their hosts through mucosal surfaces such as the lining of the respiratory tract.

Vaccination 48

Vaccination Vaccine Immune Response Development 48

Delveinsight

AUGUST 27, 2020

Moderna’s COVID-19 vaccine triggers an immune response in older adults. The phase 1 study that is being run by the National Institute of Allergy and Infectious Diseases tests three dose levels of the vaccine, mRNA-1273, given in two injections a month apart in 120 adults.

Vaccination 53

Vaccination Vaccine Research Trials 53